MoonLake Immunotherapeutics Long Term Debt

MoonLake Immunotherapeutics (MLTX) currently reports a long-term debt of $100M as of March 2026. That compares with $74M in the prior-year period — up 34.7% year over year. Use the charts on this page to explore MoonLake Immunotherapeutics's long-term debt history and peer comparisons.

MoonLake Immunotherapeutics's long-term debt increased from $74M to $100M — a 34.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MoonLake Immunotherapeutics reported $100M in long-term debt as of March 2026. That compares with $74M in the prior-year period — up 34.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $100M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MoonLake Immunotherapeutics, and consider following MLTX for alerts when major investors trade the stock.